Q2 EPS Estimates for Bio-Techne Lifted by Leerink Partnrs

Bio-Techne Corp (NASDAQ:TECH - Free Report) - Research analysts at Leerink Partnrs increased their Q2 2026 EPS estimates for Bio-Techne in a report released on Thursday, July 17th. Leerink Partnrs analyst P. Souda now expects that the biotechnology company will post earnings of $0.41 per share for the quarter, up from their previous estimate of $0.40. The consensus estimate for Bio-Techne's current full-year earnings is $1.67 per share. Leerink Partnrs also issued estimates for Bio-Techne's Q4 2026 earnings at $0.55 EPS and FY2026 earnings at $1.85 EPS.

Bio-Techne (NASDAQ:TECH - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.56 EPS for the quarter, topping analysts' consensus estimates of $0.51 by $0.05. Bio-Techne had a net margin of 10.89% and a return on equity of 13.17%. The company had revenue of $316.18 million for the quarter, compared to analysts' expectations of $317.92 million. During the same quarter in the previous year, the firm posted $0.48 EPS. Bio-Techne's revenue was up 4.2% on a year-over-year basis.

Other equities research analysts also recently issued reports about the stock. KeyCorp reaffirmed a "sector weight" rating on shares of Bio-Techne in a report on Wednesday, April 9th. Stifel Nicolaus dropped their price target on shares of Bio-Techne from $75.00 to $60.00 and set a "hold" rating on the stock in a research note on Thursday, May 8th. Wells Fargo & Company initiated coverage on shares of Bio-Techne in a research note on Friday, May 30th. They issued an "overweight" rating and a $59.00 price objective for the company. TD Cowen initiated coverage on shares of Bio-Techne in a report on Wednesday, July 9th. They set a "buy" rating and a $65.00 target price on the stock. Finally, Scotiabank cut their price target on Bio-Techne from $90.00 to $75.00 and set a "sector outperform" rating for the company in a report on Friday, July 11th. Seven analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Bio-Techne has an average rating of "Hold" and a consensus target price of $70.00.

Bio-Techne Stock Performance

Shares of TECH opened at $52.02 on Monday. Bio-Techne has a 1 year low of $46.01 and a 1 year high of $83.62. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.71 and a quick ratio of 2.58. The stock's fifty day moving average price is $50.52 and its two-hundred day moving average price is $58.13. The firm has a market cap of $8.16 billion, a PE ratio of 63.44, a PEG ratio of 2.48 and a beta of 1.39.

Hedge Funds Weigh In On Bio-Techne

A number of institutional investors have recently added to or reduced their stakes in the business. Proficio Capital Partners LLC increased its position in shares of Bio-Techne by 13.6% in the fourth quarter. Proficio Capital Partners LLC now owns 3,367 shares of the biotechnology company's stock worth $243,000 after purchasing an additional 402 shares during the last quarter. Royal London Asset Management Ltd. raised its position in shares of Bio-Techne by 17.8% during the 4th quarter. Royal London Asset Management Ltd. now owns 67,306 shares of the biotechnology company's stock valued at $4,848,000 after buying an additional 10,170 shares in the last quarter. Sei Investments Co. lifted its holdings in shares of Bio-Techne by 6.9% during the 4th quarter. Sei Investments Co. now owns 563,157 shares of the biotechnology company's stock worth $40,564,000 after acquiring an additional 36,589 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new position in Bio-Techne in the fourth quarter worth $3,774,000. Finally, LPL Financial LLC increased its stake in Bio-Techne by 10.5% in the fourth quarter. LPL Financial LLC now owns 81,801 shares of the biotechnology company's stock valued at $6,037,000 after acquiring an additional 7,777 shares during the last quarter. 98.95% of the stock is currently owned by institutional investors.

Bio-Techne Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 30th. Investors of record on Monday, May 19th were paid a dividend of $0.08 per share. This represents a $0.32 annualized dividend and a yield of 0.62%. The ex-dividend date of this dividend was Monday, May 19th. Bio-Techne's dividend payout ratio is 39.02%.

Bio-Techne declared that its board has initiated a share repurchase program on Wednesday, May 7th that permits the company to repurchase $500.00 million in shares. This repurchase authorization permits the biotechnology company to repurchase up to 6.5% of its stock through open market purchases. Stock repurchase programs are often a sign that the company's management believes its shares are undervalued.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.